Tuftsin-derived T-peptide prevents cellular immunosuppression and improves survival rate in septic mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Gao, Yu Lei ^a,b   Chai, Yan Fen ^a   Dong, Ning ^b   Han, Su ^c   Zhu, Xiao Mei ^b   Zhang, Qing Hong ^b   Yao, Yong Ming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; IMMUNOLOGIC FACTOR; INTERLEUKIN 2; MEMBRANE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUFTSIN;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELLULAR IMMUNITY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; MOUSE; PHENOTYPE; SEPSIS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, SURFACE; APOPTOSIS; CTLA-4 ANTIGEN; CYTOKINES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOPHENOTYPING; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; PHENOTYPE; SEPSIS; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA; TUFTSIN;

EID: 84947594358     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16725     Document Type: Article

References (49)

1. Gu, W. J., Wang, F., Bakker, J., Tang, L., Liu, J. C. The effect of goal-directed therapy on mortality in patients with sepsis-earlier is better: a meta-analysis of randomized controlled trials. Crit Care. 18, R570 (2014).
2. Dellinger, R. P. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 41, 580-637 (2013).
3. Gaieski, D. F., Edward, J. M., Kallan, M. J., Carr, B. G. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 41, 1167-1174 (2013).
4. Sossdorf, M. et al. Physical exercise induces specific adaptations resulting in reduced organ injury and mortality during severe polymicrobial sepsis. Crit Care Med. 41, 246-255 (2013).
5. Winters, B. D. et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med. 38, 1276-1283 (2010).
6. Taniguchi, L. U., Bierrenbach, A., Toscano, C. M., Schettino, G., Azevedo, L. Sepsis-related deaths in Brazil: an analysis of the national mortality registry from 2002 to 2010. Crit Care. 18, R608 (2014).
7. Hotchkiss, R. S., Karl, I. E. The pathophysiology and treatment of sepsis. N Engl J Med. 348, 138-150 (2003).
8. Skrupky, L. P., Kerby, P. W., Hotchkiss, R. S. Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology. 115, 1349-1362 (2011).
9. Martin, G. et al. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcome. Crit Care. 13, R103 (2009).
10. Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 306, 2594-2605 (2011).
11. Darcy, C. J. et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care. 18, R163 (2014).
12. Inoue, S. et al. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit Care Med. 41, 810-819 (2013).
13. Nascimento, D. C. et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med. 38, 1718-1725 (2010).
14. Guignant, C. et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 15, R99 (2011).
15. Hotchkiss, R. S., Monneret, G., Payen, D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 13, 862-874 (2013).
16. Chang, K. C. et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care. 17, R85 (2013).
17. Peck-Palmer, O. M. et al. Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol. 83, 1009-1018 (2008).
18. Roger, P. M. et al. The early phase of human sepsis is characterized by a combination of apoptosis and proliferation of T cells. J Crit Care. 27, 384-393 (2012).
19. Chang, K. et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 18, R3 (2014).
20. Hotchkiss, R. S., Coopermith, C. M., McDunn, J. E., Ferguson, T. A. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 15, 496-497 (2009).
21. Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., Remick, D. G. The pathogenesis of sepsis. Annu Rev Pathol. 6, 19-48 (2011).
22. Hotchkiss, R. S., Opal, S. Immunotherapy for sepsis: a new approach against an ancient foe. N Engl J Med. 363, 87-89 (2010).
23. Bodas, M., Min, T., Vij, N. Early-age-related changes in proteostasis augment immunopathogenesis of sepsis and acute lung injury. PLoS One. 5, e15480 (2010).
24. Mohr, A. et al. Sepsis leads to a reduced antigen-specific primary antibody response. Eur J Immunol. 42, 341-352 (2012).
25. Lee, S. Y. et al. Distinct pathophysiologic mechanisms of septic acute kidney injury: role of immune suppression and renal tubular cell apoptosis in murine model of septic acute kidney injury. Crit Care Med. 40, 2997-3006 (2012).
26. Liu, Q. Y., Yao, Y. M., Yu, Y., Dong, N., Sheng, Z. Y. Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4+ CD25high T cells. PLoS One. 6, e19811 (2011).
27. Chao, Y. H. et al. An increase in CD3+ CD4+ CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis. PLoS One. 9, e110338 (2014).
28. Yang, X., Hu, B., Sun, R., Chen J. Deregulation of T cell response in sepsis. Front Biosci. 19, 1370-1376 (2014).
29. Venet, F. et al. IL-7 restores lymphocyte functions in septic patients. J Immunol. 189, 5073-5081 (2012).
30. Gao, M. et al. Use of blood urea nitrogen, creatinine, interleukin-6, granulocyte-macrophage colony stimulating factor in combination to predict the severity and outcome of abdominal sepsis in rats. Inflamm Res. 61, 889-897 (2012).
31. Xiang, X. S., Li, N., Zhao, Y. Z., Li, Q. R., Li, J. S. Combination therapy with thymosin alpha 1 and dexamethasone helps mice survive sepsis. Inflammation. 37, 402-416 (2014).
32. Hutchins, N. A., Unsinger, J., Hotchkiss, R. S., Ayala, A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med. 20, 224-233 (2014).
33. Payen, D., Monneret, G., Hotchkiss, R. Immunotherapy: a potential new way forward in the treatment of sepsis. Crit Care. 17, R118 (2013).
34. Wan, J. et al. Thymosin-alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci. 16, 3004-3013 (2011).
35. Najjar, V. A.& Nishioka, K. Tuftsin: a natural phagocytosis stimulating peptide. Nature. 228, 672-673 (1970).
36. Liu, X. et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine. 30, 6527-6533 (2012).
37. Dzierzbicka, K., Wardowska, A., Rogalska, M., Trzonkowski, P. New conjugates of muramyl dipeptide and nor-muramyl dipeptide linked to tuftsin and retro-tuftsin derivatives significantly influence their biological activity. Pharmacol Rep. 64, 217-223 (2012).
38. Wu, M., Nissen, J. C., Chen, E. I., Tsirka, S. E. Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis. PLoS One. 7, e34933 (2012).
39. Baker, C. C., Gaines, H. O., Niven-Fairchild, A. T. The effect of tuftsin and splenectomy on mortality after intraabdominal sepsis. J Surg Res. 36, 499-502 (1984).
40. Wardowska, A. et al. Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis. Vaccine. 27, 369-374 (2009).
41. Nissen, J. C., Selwood, D. L., Tsirka, S. E. Tuftsin signals through its receptor neuropilin-1 via transforming growth factor beta pathway. J Neurochem. 127, 394-402 (2013).
42. An, Y. et al. Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors. Anticancer Drugs. 25, 857-867 (2014).
43. Zhu, X. M. et al. High mobility group box-1 protein regulate immunosuppression of regulatory T cells through Toll-like receptor 4. Cytokine. 54, 296-304 (2011).
44. Zhang, Y. et al. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res. 31, 249-257 (2011).
45. Powell, J. D. et al. Molecular regulation of interleukin-2 expression by CD28 costimulation and anergy. Immunol Rev. 165, 287-300 (1998).
46. Hotchkiss, R. S. et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol. 1, 496-501 (2000).
47. Liston, A., Gray, D. H. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 14, 154-165 (2014).
48. Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 501, 252-256 (2013).
49. Yadav, M. et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 209, 1713-1722 (2012).